08.05.2013 - Belgian single chain camelidae antibody producer Ablynx has started development of an anti-IgE nanobody, code-named ALV-0962.
The Ghent-based company announced the compound will enter clinical development after Q2/2014. Ablynx believes its treatment of severe allergic asthma can outcompete Roche’s /Novartis’ marketed allergic asthma antibody Xolair (omalizumab) due to its "unique" dual mode of action. The company suggested the preclinical compound could displace receptor-bound IgE as well as binding free IgE molecules.
Due to its mode of action, Ablynx believes that ALX-0962 could address a wider patient population, including those currently not eligible to be treated with omalizumab (Xolair®). Currently, many allergic asthma treatments are in clinical development including Phase II compounds from Swedish Resistentia Pharmaceuticals AB, Takeda, Actelion or Cytos Biotechnology (CYT003-QbG10).
IgE is a key mediator in initiating an allergic reaction upon allergen exposure. IgE is a clinically and commercially validated mechanism to treat allergic asthma. Omalizumab currently is the only anti-IgE biologic approved for the treatment of patients with moderate to severe persistent allergic asthma, inadequately controlled with inhaled corticosteroids. Xolair® generated sales of $1.26bn in 2012.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.